Crossmark

Schistosomiasis and HIV-1 viral load in HIV-infected outpatients with immunological failure in Tanzania: a case-control study

Crossref DOI link: https://doi.org/10.1186/s12879-019-3876-8

Published Online: 2019-03-12

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Masikini, Peter

Colombe, Soledad https://orcid.org/0000-0003-0300-902X
Marti, Amon

Desderius, Bernard

de Dood, Claudia J.

Corstjens, Paul L. A. M.

van Dam, Govert J.

Seugendo, Mwanaisha

Kalluvya, Samuel

Downs, Jennifer A.
Funding

Funding for this research was provided by:

Catholic University for Health and Allied Sciences (None)

Wurzburg Foundation (None)
License Information

Text and Data Mining valid from 2019-03-12
More Information

Article History

Received: 4 September 2018

Accepted: 4 March 2019

First Online: 12 March 2019

Ethics approval and consent to participate

: All participants were recruited after providing written informed consent. Clearance was obtained from the joint CUHAS/BMC Research Ethics Committee [CREC/037/2014]. All results were made available immediately to clinicians and recorded in the patient’s medical record. All patients with schistosome infection received praziquantel 40 mg/kg in one dose on one single day.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.